PRECISION DERMAT
PharmaPRECISION DERMAT is a pharmaceutical company focused on Dermatology.
PRECISION DERMAT at a Glance
- Fast trial execution (28 months median completion)
Upcoming FDA Decisions
Full Calendar →PRECISION DERMAT's Key Drugs
PRECISION DERMAT's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
PRECISION DERMAT's Recent FDA Approvals
New NDA/BLA approvals for PRECISION DERMAT over the last two years — novel drugs only, excluding generics and label supplements.
PRECISION DERMAT's Therapeutic Areas
PRECISION DERMAT's approved drugs and pipeline span 1 therapeutic area, led by Dermatology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PRECISION DERMAT's Top Competitors
PRECISION DERMAT's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PRECISION DERMAT Pipeline Snapshot
PRECISION DERMAT has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/0 completed
- • Speed: 28 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1982-10-29
- Latest
- 2024-10-03
- Applications
- 2
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges